Consistent with the TET-inhibitory action of Epag, analysis of the genomic DNA of the PBMCs of patients with aplastic anemia demonstrated a treatment-associated increase in the global cytosine methylation, an effect comparable to that observed in normal bone marrow in vitro but not with the structurally unrelated TPO-R agonist, Apag or rTPO. This evidence concerns the gene DIAPH2-AS1 and idiopathic aplastic anemia.